sunitinib mylan 12.5 mg kapseli, kova
mylan ab - sunitinib - kapseli, kova - 12.5 mg - sunitinibi
sunitinib mylan 25 mg kapseli, kova
mylan ab - sunitinib - kapseli, kova - 25 mg - sunitinibi
sunitinib mylan 37.5 mg kapseli, kova
mylan ab - sunitinib - kapseli, kova - 37.5 mg - sunitinibi
sunitinib mylan 50 mg kapseli, kova
mylan ab - sunitinib - kapseli, kova - 50 mg - sunitinibi
sunitinib accord
accord healthcare s.l.u. - sunitinibi - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiset aineet - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
sunitinib ratiopharm 12.5 mg kapseli, kova
ratiopharm gmbh - sunitinib - kapseli, kova - 12.5 mg - sunitinibi
sunitinib ratiopharm 25 mg kapseli, kova
ratiopharm gmbh - sunitinib - kapseli, kova - 25 mg - sunitinibi
sunitinib ratiopharm 37.5 mg kapseli, kova
ratiopharm gmbh - sunitinib - kapseli, kova - 37.5 mg - sunitinibi
sunitinib ratiopharm 50 mg kapseli, kova
ratiopharm gmbh - sunitinib - kapseli, kova - 50 mg - sunitinibi
sunitinib sandoz 12.5 mg kapseli, kova
sandoz a/s - sunitinib - kapseli, kova - 12.5 mg - sunitinibi